Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder

Table 1 Predictors of Significant Weight Gain: Patient Characteristics and Weight Changes During Acute Olanzapine Treatment

	Study 1 (N = 669)			Study 2 (N = 102)
Predictors of weight gain	Value	Correlation^a with weight change at endpoint	Correlation^a with 7% WG at endpoint	Value	Correlation^a with weight change at endpoint	Correlation^a with 7% WG at endpoint
Baseline BMI,^b kg/m²	26.1 (5.1)	- 0.16***	- 0.20***	26.7 (5.6)	- 0.21*	- 0.25*
Age,^b years	38.9 (11.5)	- 0.18***	- 0.18***	35.9 (10.8)	- 0.09	- 0.02
Caucasian^c N (%)	549 (82.1%)	- 0.08*	- 0.06	81 (79.4%)	- 0.13	- 0.10
Men^c N (%)	431 (64.4%)	0.08*	0.04	68 (66.7%)	- 0.06	- 0.06
Weight change from baseline^b
At Week 1, kg	0.50 (1.7)	0.28***	0.24***	0.47 (1.9)	0.19	0.17
At Week 2, kg	1.1 (2.1)	0.41***	0.34***	1.0 (2.3)	0.44***	0.35***
At Week 3, kg	1.5 (2.5)	0.46***	0.39***	1.6 (2.4)	0.43***	0.33***
At Week 4, kg	1.9 (2.6)	0.53***	0.45***	2.0 (2.5)	0.51***	0.44***
At endpoint,^d kg	5.4 (6.9)			5.2 (6.6)

ISSN: 1471-244X